A phase IV study of homoharringtonine, cytarabine, aclacinomycin and G-CSF (HCAG) regimen compared with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia patients
10.3969/j.issn.1674-8115.2017.08.010
- Author:
Zhao LIU
;
Yunxiang ZHANG
;
Lining WANG
;
Zheng XIA
;
Yuanfei MAO
;
Huijin ZHAO
;
Jianhua YOU
;
Yang YU
;
Yubing ZHAO
;
Yuhong REN
;
Ya LI
;
Yan WANG
;
Qiusheng CHEN
;
Junmin LI
;
Yu CHEN
- Keywords:
homoharringtonine;
long-term survival;
risk factors;
acute myeloid leukemia;
elderly patient
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2017;37(8):1100-1105
- CountryChina
- Language:Chinese
-
Abstract:
Objective · To compare the efficacy and prognostic factors of HCAG regimen with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia (AML) patients. Methods · Forty-one patients with AML (aged 55-71 years) were randomly divided into two groups (Group HCAG and Group IA) between 2014 and 2016 for induction and consolidation therapy. Multivariate analysis was applied to identify prognostic factors for relapse-free survival (RFS). Results · A total of 29 patients (70.7%) achieved complete remission (CR). The estimated 2-year overall survival (OS) was 66.8% in Group HCAG and 75.4% in Group IA (P=0.913). The estimated 2-year RFS was 61.8% in Group HCAG and 49.1% in Group IA (P=0.411). Age remained as the unfavorable prognostic factor, leading to significant differences in OS and RFS. In addition, RFS was influenced by cytogenetic/molecular risk stratification. Conclusion · Although HCAG seemed not to particularly benefit the group, the dose reduction of anthracyclines may be applied in elderly patients with comparable short-time outcome. Furthermore, the introduction of homoharringtonine resulted in an improvement of treatment response for more than 20% compared with CAG regimen.
